Abstract:Objective: To compare the remission of early abnormal glucose metabolism in patients with polycystic ovary syndrome (PCOS) treated with metformin, pioglitazone and their combination, and to explore the effective clinical treatment of early abnormal glucose metabolism in patients with PCOS. Methods: A total of 150 patients diagnosed with PCOS according to Rotterdam criteria accompanied with abnormal glucose metabolism were enrolled from the Department of Endocrinology and Metabolism of The Second Affiliated Hospital of Chongqing Medical University from March 2018 to September 2020. According to different treatment drugs, they were equally randomized into three groups: group A (50 patients) treated with metformin (1 500 mg/d) , group B (50 patients) treated with pioglitazone (30 mg/d) and group C (50 patients) treated with their combination (metformin 1 000 mg/d, pioglitazone 30 mg/d) . The levels of fasting and 2 h postprandial blood glucose, hemoglobin A1c (HbA1c) , homeostasis model assessment-insulin resistance (HOMA-IR) , and fasting insulin were observed in the three groups before and after the three-month treatment, and the clinical treatment effects, especially the remission of early abnormal glucose metabolism, were evaluated in the three groups. Results: The improvement rate of 2 h postprandial blood glucose, fasting insulin and HOMA-IR after the treatment, the remission rate of abnormal glucose metabolism in group B and C were significantly higher than those in group A (P<0.05) . There were no significant differences in the improvement rate of the fasting blood glucose and HbA1c after the treatment among the three groups (P>0.05) . Conclusion: Pioglitazone and their combination have a better therapeutic effect on the metabolism of PCOS patients, which can effectively reduce blood glucose and improve insulin resistance, helping to alleviate the early abnormal glucose metabolism of PCOS patients, providing a theoretical basis for clinical treatment and improving the long-term quality of life of PCOS patients.
